Abarelix is a potent gonadotropin-releasing hormone (GnRH) antagonist used in the treatment of advanced prostate cancer by rapidly suppressing testosterone production. As a synthetic decapeptide, it functions… Read more
Abarelix is a potent gonadotropin-releasing hormone (GnRH) antagonist used in the treatment of advanced prostate cancer by rapidly suppressing testosterone production. As a synthetic decapeptide, it functions by competitively binding to GnRH receptors in the pituitary gland, preventing the release of luteinizing hormone and follicle-stimulating hormone. Pharmaceutical laboratories utilize Abarelix reference standards, along with related impurities and metabolites, to ensure rigorous quality control and precise impurity profiling during drug development. Stable isotope labelled compounds, such as Abarelix-d7, are critical for method validation and accurate quantification in complex biological matrices, especially when conducting mass spectrometry-based bioanalytical assays. These high-quality reference materials support the precise monitoring of drug substance stability and the detection of degradation products, ensuring compliance with regulatory requirements throughout the lifecycle of pharmaceutical research and production.